<DOC>
	<DOCNO>NCT00098761</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , VNP40101M , work different way stop tumor cell divide stop grow die . PURPOSE : This phase I trial study side effect best dose VNP40101M treat young patient recurrent , progressive , refractory primary brain tumor .</brief_summary>
	<brief_title>VNP40101M Treating Young Patients With Recurrent , Progressive , Refractory Primary Brain Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose dose-limiting toxicity VNP40101M pediatric patient recurrent , progressive , refractory primary brain tumor . Secondary - Determine pharmacokinetics drug active metabolite VNP4090CE patient . - Determine efficacy drug patient . OUTLINE : This dose-escalation , multicenter study . Patients stratify accord receive ≥ 1 follow prior therapy : craniospinal irradiation ( yes v ) , autologous bone marrow transplant ( yes v ) , &gt; 2 myelosuppressive chemotherapy myelosuppressive biologic therapy regimen ( yes v ) . Patients receive VNP40101M IV 30 minute day 1-5 . Treatment repeat every 42 day 8 course absence disease progression unacceptable toxicity . Cohorts 2-6 patient per stratum receive escalate dos VNP40101M maximum tolerate dose ( MTD ) determine . The MTD define dose 25 % patient experience dose-limiting toxicity . A total 12 patient treated MTD . Patients follow 3 month . PROJECTED ACCRUAL : A total 4-60 patient ( 2-30 per stratum ) accrue study within 18 month .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirmed* primary brain tumor , include benign brain tumor ( e.g. , lowgrade glioma ) Recurrent progressive disease OR refractory standard therapy NOTE : *Patients intrinsic brain stem diffuse optic pathway tumor require histological confirmation , must clinical and/or radiographic evidence disease progression No bone marrow disease PATIENT CHARACTERISTICS : Age 21 Performance status Karnofsky 50100 % ( patient &gt; 16 year age ) OR Lansky 50100 % ( patient ≤ 16 year age ) Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3* Platelet count ≥ 100,000/mm^3* Hemoglobin ≥ 8 g/dL* NOTE : *Unsupported Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT AST ≤ 2.5 time ULN No overt hepatic disease Renal BUN &lt; 25 mg/dL Creatinine ≤ 1.5 time ULN age OR Glomerular filtration rate &gt; 70 mL/min No overt renal disease Cardiovascular Shortening fraction ≥ 30 % echocardiogram OR Ejection fraction ≥ 50 % gate radionucleotide study No clinically significant cardiac arrhythmia EKG No overt cardiac disease Pulmonary DLCO ≥ 60 % predict Chest Xray normal ( defined absence pulmonary infiltrates , pneumonitis , pleural effusion , pulmonary hemorrhage , fibrosis ) AND rest pulse oximetry read &gt; 94 % room air ( patient perform DLCO ) No overt pulmonary disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Neurologic deficit allow provide deficit progression ≥ 1 week study entry No uncontrolled infection No known hypersensitivity polyethylene glycol PRIOR CONCURRENT THERAPY : Biologic therapy At least 6 month since prior allogeneic bone marrow stem cell transplantation At least 3 month since prior autologous bone marrow stem cell transplantation More 1 week since prior colonystimulating factor ( e.g. , filgrastim [ GCSF ] , sargramostim [ GMCSF ] , epoetin alfa ) At least 3 week since prior myelosuppressive anticancer biologic therapy No concurrent routine colonystimulating factor Chemotherapy At least 3 week since prior myelosuppressive anticancer chemotherapy ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy Concurrent corticosteroid allow provide dose stable decrease ≥ 1 week study entry Radiotherapy At least 3 month since prior craniospinal irradiation ≥ 18 Gy At least 2 week since prior focal irradiation primary tumor and/or symptomatic metastatic site Surgery Not specify Other At least 7 day since prior nonmyelosuppressive anticancer therapy At least 7 day since prior investigational agent Concurrent enzymeinducing anticonvulsant drug allow No concurrent anticancer experimental agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood grade I meningioma</keyword>
	<keyword>childhood grade II meningioma</keyword>
	<keyword>childhood grade III meningioma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
</DOC>